The U.S. Food and Drug Administration has approved GSK's prefilled syringe presentation of Shingrix (zoster vaccine ...

Administering Shingrix previously required combining a lyophilised antigen with a liquid adjuvant from two separate vials.

Patients with inflammatory arthritis would benefit from vaccination against herpes zoster, with the Shingrix vaccine showing a crude effectiveness of 50%.

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a prefilled syringe presentation of SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) for the ...

The newly approved prefilled syringe version of Shingrix is expected to simplify administration and supports efforts to ...

The retrospective cohort study included more than 130,000 people in the US. It reveals that the shingles vaccine (called ...

This new Shingrix vaccine presentation eliminates the need for reconstitution, simplifying the administration process for ...

The Food and Drug Administration (FDA) has approved a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

The FDA has approved a prefilled syringe option of Shingrix which will streamline administration of GSK’s herpes zoster ...

The U.S. Food and Drug Administration approved a pre-filled syringe version of GSK's blockbuster shingles vaccine Shingrix, ...

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for a prefilled syringe presentation of ...

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and expert industry news.